MBX Biosciences (MBX) Other Non-Current Liabilities (2023 - 2026)

MBX Biosciences has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $1000.0 for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1000.0, down 95.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1000.0 (down 95.65% YoY), and the FY2025 annual result was $2000.0, down 95.24% from the prior year.
• Other Non-Current Liabilities came in at $1000.0 for Q1 2026 at MBX Biosciences, down from $2000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $194000.0 in Q4 2023 to a low of $1000.0 in Q1 2026.
• The 4-year median for Other Non-Current Liabilities is $19000.0 (2025), against an average of $44000.0.
• Across the five-year window, Other Non-Current Liabilities tumbled 78.35% in 2024 and tumbled 95.65% in 2026, its largest moves.
• MBX Biosciences' Other Non-Current Liabilities stood at $194000.0 in 2023, then sank by 78.35% to $42000.0 in 2024, then slumped by 95.24% to $2000.0 in 2025, then slumped by 50.0% to $1000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $1000.0 (Q1 2026), $2000.0 (Q4 2025), and $7000.0 (Q3 2025), per Business Quant data.